Exact Sciences (NASDAQ:EXAS) Q3 results:
Revenue: $218.8M (+85%).
Cologuard test volume: 45K (+89%). Average revenue/test: $479 (-3%). Average cost/test: $114 (-8%).
Net loss: ($40.6M) (+11%); loss/share: ($0.31) (+16%).
2019 guidance: Revenue: $802M – 810M from $800M – 810M.
Shares down 14% after hours.
Previously: EXACT Sciences EPS beats by $0.10, beats on revenue (Oct. 29)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.